Douglas Pharmaceuticals Ltd

Slides:



Advertisements
Similar presentations
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Advertisements

PLIVA, a Member of the Teva Group Tihomir Oreskovic
Empowering healthier lives Vitaco Health (NZ) Ltd.
Henkel’s Stage-Gate Process (Portugal Division)
Torrent Pharmaceuticals Ltd Investor Presentation Q1 FY 2012.
Update on Penn Pharma John Roberts, Commercial Director December 2012.
Torrent Pharmaceuticals Ltd Investor Presentation Q2 FY 2012.
Management Discussion Report FY Index Key Financial Numbers Operating Margins Balance Sheet Summary Performance Highlights Business Operations.
CIPLA LTD Analyst Report By Siddharth Ghaisas. WHO IS CIPLA & WHAT DO THEY DO? WHO WHO - The Chemical, Industrial & Pharmaceutical Laboratories; - Founded.
New Patent Issue: BioPharma Royalty Trust by Eugene Li Summary of pages From Ideas to Assets - Part 22.
Torrent Pharmaceuticals Ltd Investor Presentation FY 2011.
Corporate Presentation INDOCO REMEDIES LTD. About Us  Indian Company with an International presence  Turnover 09-10; Rs Crores  Among the fastest.
Food Safety Export Assurance System Requirements for Dairy Products Confidential to Fonterra Co-operative Group September 2014 Malcolm Bailey – Fonterra.
Patent linkage and the TPP Commercial considerations relevant to TPP 1 Geraldine Storton Hospira Pty Ltd.
Services Export Unit Assisting services providers to realize their export potential.
Sunny, Nick, Laura, Jie, Brad and Jamie Introduction During the 1960’s and 1970’s, Xerox seemed invincible in the copier industry In 1959, Canon entered.
Delivering the Present Creating the Future Moving from Evolution to the Engagement Revolution 1 Presented by : John Healy Head of GSI Commerce Global.
Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology.
DAVID HARDING CPhI 2008 SHANGHAI JUNE 24–26, 2008 Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success.
Balance of Payments Division Statistics Canada Statistics Canada Programmes Addressing Globalization Art Ridgeway Balance of Payments Division July 2007.
Jan 2009 INTRODUCTION TO JUBILANT FULLY INTEGRATED SOLUTIONS IN GENERICS.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Automobile Industry: The Case of Geely Motors Liesl Martin & Royce Kuzwayo.
ENTERPRISE ‘ Who to Talk to’ Expo 2015 Tipperary Enterprise Week.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
LSS and Commercialisation in MSD Daniel J. Hoey Merck Sharp & Dohme (Ireland) Ltd. 16 th October, 2009.
PRODUCT TRANSFER.
( An IACBE Accredited Institution ) Industry Analytics Post Graduate Programme (2010 – 12) 3rd Term Alliance Business School Bangalore.
Partners in Globalisation UK Trade & Investment British Business Group in Mumbai & Pune Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the.
Accelerating Development Using Open Source Software Black Duck Software Company Presentation.
ABLE LABORATORIES, INC.. Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements or other written.
13-1 Copyright © 2009 Pearson Education, Inc. publishing as Prentice Hall Part Five Global Strategy, Structure, and Implementation Chapter Thirteen Export.
Annual Meeting March 19, The “Worlds” of FHC 2 ConsumerGlobal Public Sector Global Market $4-6 Billion Family Planning HIV/AIDS Global Condom Public.
Product Management. Facts about Product Management Many managers realized that investment in INNOVATION is critical for future growth & even in the survival.
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
Torrent Pharmaceuticals Ltd Investor Presentation FY 2011.
Torrent Pharmaceuticals Ltd Investor Presentation Q3 FY 2011.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
13-1 Copyright © 2009 Pearson Education, Inc. publishing as Prentice Hall Export And Import Strategies.
Lupin Press Meet, October 7, 2003 Lupin Press Meet October 7, 2003.
Protection of Intellectual Property in Canada George Jackowski, Ph.D., KCTJ October 19 th, 2015 Chairman of NAVA Corp.
Global Graphics Tablet Industry 2015 Deep Market Research Report TELEPHONE:
Career opportunities in medical research. Basic research.
LICENSING PRESENTATION September 2013
Uniting Forces for Access to Hepatitis C Treatment Global Epidemiology Global Epidemiology & Treatment Access Issues & Treatment Access Issues Tracy Swan.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
1 CL NPD Process Evaluation Yanyi Wang NYU Mastering New Product and Service Process Fall 2004.
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Global Polyetheretherketone Industry Policy, Growth & Size Research Report Published: Apr 2015 Single User License: US$ 2600 Corporate User License: US$
Global Beta Cyfluthrin Industry Size, Trends, Segmentation Research 2015 Published: Sep 2015 Single User License: US$ 2800 Corporate User License: US$
Introduction to Impax Laboratories (Taiwan), Inc. 益邦製藥股份有限公司 June 2009.
Angel Semerdjiev Commissioner State Energy and Water Regulatory Commission Bulgaria Budapest, Hungary April 14, th Annual Meeting of the Energy.
Market Research on Global Weight Loss Pills Industry Trends Survey and Prospects Report Published: Apr 2016 Single User License: US $2800 Corporate.
Allergy Drugs Markets in China Published on : Jun 2014.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Market Research Report Global and Chinese Zinc dithiophosphateIndustry, Market Research Report.
MarketsandMarkets Presents Global Water Treatment Chemicals Market in Soft Drinks By Type, Region and Process (2010 – 2015)
Nucleus Replacement Medical Devices Market Size, Share & Forecast
Torrent Pharmaceuticals Ltd
Success Stories of Globalization in Korean Pharma
The Social Network Platform
GEORGIAN ELECTRICITY MARKET OPERATOR
Business Case Development Key Components :
Bio-Facility Qualification, Start-Up & Licensure
الفصل الاول مقدمة لادارة الاعمال الدولية
Export And Import Strategies
European Innovation Council
Presentation transcript:

Douglas Pharmaceuticals Ltd Graeme Douglas Managing Director

Company history Year Key Event 1967 Trading commences 1972 Frusemide registered 1983 Penicillin plant commissioned (solid oral in ‘85) 1986 Purchase of Karitane product license 1988 Loss of 3 major agencies 1989 First Australian market product registration 1990 Henderson site opened (new plant in 1996) 1996 Sale of Karicare to Nutricia 2002 Isotretinoin first registered in Europe 2006 Sale of Australian subsidiary 2007 FDA Approval 2008 Purchase of nutraceutical business line 2010 Added softgel capacity to manufacturing capabilities

Sales Growth Growth In Revenue 1967 – 2011B (NZ$m’s) CAGR 14%

Registration & Licensing Product Development Process Ideas Product Design Evaluation Detailed Scoping Scale-up Bio-studies Registration & Licensing Launch Company Strategy Market Assessment Patent Search Feasibility API Source Formulation Analytical Validation Pilot Scale Large Scale Validation Stability Regulatory Costings Licensing Stability Clinical Stability                              G7 G6 G5 G4 G3 18-36 Months NZ$0.5 to 1.5Mn G2 G1 6-12 Months NZ$0.3 to 1Mn 2-10 Months NZ$0.5 to 1.5Mn 12 - 24 Months NZ$0.5 to 2Mn TOTAL (per Project) 3.5 - 7.5 years duration and NZ$ 2.0 to 6.0Mn 3-6 Months NZ$ 70K

Continued Investment in R&D Douglas Pharmaceuticals Turnover and R&D Spend (2004 – 2011B) NZ$M’s NZ$M’s Annual Turnover Annual R&D Spend

Oratane (Isotretinoin Softgel Capsules) Isomer of Vitamin A acid Highly effective treatment for Acne Product is a challenge to develop, manufacture & register Douglas developed the first generic A huge success for Douglas: 40 customers in 26 countries Oratane has annual sales of over NZ$ 40 million

Global Growth Accelerated Product and New Market Growth Are Key Elements of Our 2015 Growth Strategy Existing markets New markets Key Objectives 2010 2015 Number of Douglas Developed Products 23 45 Total Sales Revenues (Domestic and Export) $139m $250m

Thank You